Roy A. Whitfield

Station X, Inc. develops software products for scientists and clinicians. It provides products to scientists who work with large-scale human genome information in either a research or clinical setting, enabling them to extract maximal biological meaning from complex genomic data. The company was founded by Richard D. Goold, Tod M. Klingler and Andrew R. MacBride in August 2010 and is headquartered in San Francisco, CA.

The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA.

InterWest Partners LLC (InterWest Partners) is a venture capital firm founded in 1979 by Wally Hawley, Scott Hedrick and Gene Barth. The firm is headquartered in San Francisco, California.

Solexa, Inc. used to create DNA cloning and analyses technologies to enhance gene discovery. It also used to provide genomics, genetics and proteomics technologies to assist the customers in the field of pharmaceutical and agriculture. The company was located in Hayward, CA.

Sciona, Inc. provides health and nutrition recommendations. It researches and develops DNA screens for common gene variants that affect an individual's response to food, medications and the environment. These genetic screens serve as the basis for providing personalized advice to consumers. The company was founded by Rosalynn Gill-Garrison and Gareth Roberts on June 8, 2000 and is headquartered in Boulder, CO.

BioSeek, an Asterand company, is improving the success rate of pharmaceutical research and development by integrating human biology from the earliest stages of drug discovery onward. Their BioMAP® Systems incorporate predictive primary human cell-based disease models that generate uniquely informative biological activity profiles for each potential drug. As a result, their technology drives the selection and development of new drug candidates. they leverage their BioMAP® Systems technology in collaborations to enhance the productivity of their pharmaceutical partners' pipelines to identify promising compounds for therapeutic development. Asterand plc acquired BioSeek on February 18, 2010. Asterand is the leading global supplier of high quality, well characterized human tissue and human tissue-based research services to drug discovery scientists. BioSeek's BioMAP® platform and primary human cell based assays are highly complementary to the human tissue-based products and services offered by Asterand. Formed in January 2006 from the merger of Asterand, a human tissue biorepository, and Pharmagene, a human tissue-based drug discovery company, Asterand plc is uniquely positioned to provide a comprehensive approach to meet the research needs of pharmaceutical and biotechnology companies. From their offices in Royston (United Kingdom), San Francisco, California and Detroit, Michigan they have more than 90 employees focused on providing services and products to accelerate drug discovery research from target identification through to compound evaluation and drug safety.